ASLAN Pharmaceuticals announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr. Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr. Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd. Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs. Kathleen spent over 20 years at Merck & Co where she held a number of leadership positions, including Senior Vice President and Head of Worldwide Basic Research, with oversight of all the company’s global research projects, and Senior Vice President, External Discovery and Preclinical Sciences. She was also Chair of the Respiratory Worldwide Business Strategy Team, reporting directly to the Chief Executive Officer. Damien Lim, representative of BV Healthcare II Pte Ltd, has transitioned off the board with effect from March 18, 2021, after serving for 10 years.